Host: The Japanese Pharmacological Society
Name : The 97th Annual Meeting of the Japanese Pharmacological Society
Number : 97
Location : [in Japanese]
Date : December 14, 2023 - December 16, 2023
MPS (microphysiological systems) are attracting attention worldwide as useful tools for emerging in vitro assessments, with the aim of improving human extrapolation, replacing animal experiments, and reducing drug development costs.
We are developing a contractility assay system using 3D cardiac tissue composed of human iPS cardiomyocytes (hiPS-CMs) as an evaluation system to predict the side effects of congestive heart failure caused by anticancer drugs. Furthermore, we are exploring suitable culture conditions for co-culturing with liver cells and aiming to develop a cardiac toxicity assessment that takes into account liver metabolism by integrating the 3D cardiac tissue into a kinetic pump integrated microfluidic plate.
Thus, we are developing evaluation systems and applications in terms of cardiac MPS. However, in order to social implementation and further utilize the MPS in regulatory acceptance, it is necessary for academia, industry, and government to collaborate and discuss. To put this into practice, the Japan MPS consortium was launched. In this presentation, I also would like to introduce some of the activities of this consortium.
